Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Tonix Pharmaceuticals announced it has secured a second commercial payer agreement effective June 1, 2026, with a leading group purchasing organization (GPO), increasing commercial insurance coverage of its fibromyalgia drug TONMYA® to approximately 52 million U.S. lives. This milestone follows an earlier agreement and enhances patient access to th…